Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole vs Caspofungin/Voriconazole in Invasive Candida Infections
NCT00413218Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2007
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of isavuconazole in candidemia and invasive candidiasis, sponsored by Astellas Pharma. Primary endpoint: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy. Started Mar 2007; status: completed.
02
Drugs
isavuconazole
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT00413218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413218.